Company profile: Atossa Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for breast cancer, including proprietary (Z)-endoxifen, a SERM for prevention and treatment, and clinical studies: EVANGELINE Phase 2 neoadjuvant trial in ER+/HER2- pre-menopausal women; Karisma Endoxifen Trial to reduce mammographic breast density; and I-Spy 2 evaluating endoxifen to lower recurrence risk in ER+ invasive breast cancer.
Products and services
- EVANGELINE Study: A Phase 2 neoadjuvant trial comparing (Z)-endoxifen with exemestane plus goserelin for ER+/HER2- breast cancer in pre-menopausal women
- I-Spy 2 Trial: Evaluates (Z)-endoxifen in the Endocrine Optimization Pilot Protocol for ER+ invasive breast cancer patients, aiming to reduce recurrence risk
- (Z)-endoxifen: A proprietary Selective Estrogen Receptor Modulator developed for multiple breast cancer settings, including prevention and treatment, for modulating ER activity in estrogen-responsive disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atossa Therapeutics
Clene
HQ: United States
Website
- Description: Provider of nanomedicine therapeutics for neurodegenerative diseases (ALS, MS, Parkinson's Disease), infectious diseases, and oncology applications: CNM-Au8 oral gold nanocrystals; CNM-ZnAg zinc-silver ionic solution with antiviral/antimicrobial properties; CNM-AgZn17 topical silver/zinc gel for infections and wound healing; CNM-PtAu7 gold-platinum nanotherapeutic with efficacy across tumor cell lines in initial research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clene company profile →
Cellics Therapeutics
HQ: United States
Website
- Description: Provider of biomimetic nanomedicines based on cellular nanosponges—nanoparticles coated with cell membranes—to bind and neutralize bacterial toxins, cytokines, and viruses. Products include CTI-005, a red blood cell nanosponge for MRSA pneumonia, and CTI-111, a macrophage nanosponge for sepsis that absorbs and neutralizes toxins and inflammatory cytokines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellics Therapeutics company profile →
Crossject
HQ: France
Website
- Description: Provider of needle-free drug self-injection solutions, manufacturing and marketing ZENEO, a needle-free auto-injector enabling self-administration through the skin in less than a tenth of a second. Offers core needle-free technology and conducts R&D on self-injection systems, with seven products under development primarily for emergency situations and improving emergency medicine administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crossject company profile →
Lyra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for ear, nose, and throat diseases, including LYR-210 and LYR-220, bioabsorbable nasal mesh implants that deliver up to six months of continuous mometasone furoate for chronic rhinosinusitis, and the XTreo platform, a proprietary technology for direct, consistent, sustained drug delivery to affected tissues with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lyra Therapeutics company profile →
Xanadu Bio
HQ: United States
Website
- Description: Provider of nanoparticle delivery technology for mRNA and other nucleic acids, using PACE platform technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanadu Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atossa Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atossa Therapeutics
2.2 - Growth funds investing in similar companies to Atossa Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atossa Therapeutics
4.2 - Public trading comparable groups for Atossa Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →